Gut health matters in weight management. Our platform is designed to support it.
azh-biotics® is a microbiome-based companion platform for people before, during and after weight-loss treatment — built around how people actually feel on their journey.
What users are telling us
Swiss Obesity Experience Program (SOEP)
94%
Improved digestion
Reported an improved digestive experience on GLP-1.
9.5/10
Would recommend
Average likelihood to recommend at day 90.
SOEP, Azento Health patient-experience programme, Aug 2026. Uncontrolled; descriptive only.
Customer satisfaction survey
90%
Easy to use
Simple to fit into a daily GLP-1 routine.
8.7/10
Would recommend
Consistently high across commercial users.
Azento Health customer satisfaction survey, Jan 2026; n on file. Uncontrolled; descriptive only.
Real stories
Inge’s journey with Forte80®
GLP-1 and weight-loss treatments can bring side-effects. But you can do something about them. Inge from Switzerland shares her story.
Before
“I was suffering from regular, unpredictable spells of nausea, gastritis, fatigue and feeling depressed.”
The difference
“Since I started taking Forte80, I have no more side-effects at all. All have stopped.”
Her advice
“Prepare your system with Forte80 first.”
Forte80® is built on the azh-biotics® microbiome platform. Individual experience; results may vary.
Supporting the next phase of obesity care — driven by science and unmet needs
Modern obesity treatments are transforming weight management. GLP-1 and next-generation anti-obesity medicines can deliver clinically meaningful weight loss — but they also create new needs across the patient journey.
These treatments work partly by reducing appetite. Total calorie intake may fall by 16–39%, which supports weight loss — but also changes the gut environment. Less food, altered nutrients, delayed gastric emptying and common digestive side-effects create new needs around digestive comfort, gut health and long-term wellbeing.
49%
of negative experiences with modern anti-obesity medications are linked to side-effects — ahead of cost and access.
IQVIA Social Intelligence data
Clinical evidence
Made for GLP-1. Studied with GLP-1.
Better Weight Loss: Weight Loss + Wellbeing. Together.
Graphically reproduced from human clinical study.
Made for GLP-1. Studied with GLP-1.
A microbiome companion designed for weight-loss support and studied in a randomized, placebo-controlled clinical trial in people receiving GLP-1 therapy.
Feel better as the scale goes down.
10 out of 10 quality-of-life parameters improved — supporting how patients feel, function and experience their weight-loss journey.
Better weight loss. For more people.
Helping more patients achieve meaningful weight-loss outcomes on a GLP-1. Joint weight-loss and wellbeing responder differences of +9.7 to +19.1 pp.
Better weight loss is about what happens on the scale — and what happens to the person.
